EspeRare is participating in the 21st World Congress in Fetal Medicine, happening in Lisbon, Portugal, from June 23rd to June 27th, 2024.
We are excited to showcase our groundbreaking prenatal Edelife clinical study and to delve into the latest advancements in the field of prenatal medicine. This congress provides an exceptional platform to exchange insights and collaborate with leading experts dedicated to enhancing fetal health and care.
If you are attending and would like to exchange ideas or meet with the EspeRare team, please connect with Agnes Jaulent and Sebastien Mazzuri, who will be on-site at the congress. For more information about the congress and to register, please visit the following link: https://fetalmedicine.org/courses-n-congress/fmf-world-congress
EspeRare Foundation and the Pierre Fabre Group run a pivotal clinical trial, Edelife, aimed at confirming the safety and efficacy of ER-004, a prenatal treatment for XLHED (X-linked Hypohidrotic Ectodermal Dysplasia), a rare and debilitating congenital disease. Upon positive results, the study could lead to the first approved in-utero treatment for XLHED by 2026.
For more information on the Edelife clinical trial please follow the link: XLHED Ectodermal Dysplasia ER004 Clinical Study (edelifeclinicaltrial.com)
